Semaglutide currently has more long-term cardiovascular data , while tirzepatides ongoing trials aim to determine whether it can deliver similar heart-protective benefits
About CagriSema Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program)
Continuous vs Burst C Rating on LiPo Batteries Continuous and burst C rating can be confusing, especially if youre a beginner
Given the theoretical cancer concern (disrupting senescence surveillance) and absence of human pharmacokinetic data, caution is warranted
Having certain changes in the genes or hereditary syndromes, such as basal cell nevus syndrome, that are linked to skin cancer
This service is not intended to diagnose, treat, cure, or prevent any disease.